Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

Managing the Complex Patient with Chronic Pain for the Non-Pain Specialist

neuroscienceCME Multimedia Snack

Premiere Date: Thursday, November 6, 2014

This activity offers CE credit for:

1. Physicians (CME)
2. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Friday, November 6, 2015
Note: Credit Is No Longer Available

Faculty

Charles B. Nemeroff, MD, PhD  Professor and Chair Department of Psychiatry Mulva Clinic for the Neurosciences Director, Institute of Early Life Adversity Research Dell Medical School The University of Texas at Austin Austin, TX

David L. Caraway, MD, PhD  Medical Director Center for Pain Relief Tri State, PLLC Huntington, WV

Statement of Need

According to Phillip Pizzo, MD, of Stanford University School of Medicine, “clinicians’ limited understanding of pain remains a major barrier to effective pain management.”¹ The Centers for Disease Control and Prevention (CDC) reports that one in four adults in the United States said that they had experienced pain lasting longer than 24 hours in the previous month, and of those, 42% said it had lasted for at least one year.²

Since pain is so ubiquitous, physicians of all specialties are likely to treat patients who present with pain symptoms and may be in need of referral, or who are also seeing a pain specialist or primary care provider who is managing their pain. This neuroscienceCME Snack offers non-pain specialists unique perspectives in chronic pain management, emphasizing the importance of applying a collaborative approach to patient care.

---

1. Pizzo PA, Clark NM; Board on Health Sciences Policy of the Institute of Medicine [IOM]. Relieving pain in America: a blueprint for transforming prevention, care, education, and research. IOM Website. http://www.iom.edu/Reports/2011/Relieving-Pain-in-America-A-Blueprint-for-Transforming-Prevention-Care-Education-Research.aspx. Published June 29, 2011. Accessed October 25, 2014.
2. Centers for Disease Control and Prevention [CDC]. National Health and Nutrition Examination Survey: key statistics for chronic pain. CDC Website. http://www.cdc.gov/nchs/nhanes/bibliography/key_statistics.aspx. Published 2002. Accessed October 25, 2014.

Activity Goal

This educational activity centers on the CME Outfitters Make One Change statement. This statement is crafted from pertinent quality measures or clinical guidelines as a performance challenge to all participants. The Make One Changestatement for this activity is:

Devise individualized treatment plans that include an assessment of all available therapies, pharmacological and nonpharmacological, for the optimal management of chronic pain.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Apply a multimodal and multidisciplinary approach when assessing available pain management strategies to improve the quality of life in patients with chronic pain.
• Engage patients in shared treatment planning and development of long-term goals for pain management.

Financial Support

This activity is supported by CME Outfitters, LLC.

Target Audience

Physicians and other health care professionals with an interest in chronic pain.

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST928 (requires free account activation), and participants can print their certificate or statement of credit immediately (80% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Nemeroff has disclosed that he receives grants/research support from the National Institutes of Health (NIH). He serves as a consultant to Allergen, Inc.; Eli Lilly and Company; Lundbeck; Mitsubishi Tanabe Pharma Development America; Prismic Pharmaceuticals; SK Pharma; Roche; Shire Pharmaceuticals; Taisho Pharmaceutical Inc.; Takeda Pharmaceuticals North America, Inc.; and Xhale, Inc. He serves on the scientific advisory boards of the American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); CeNeRx BioPharma; National Alliance for Research on Schizophrenia and Depression (NARSAD); PharmaNeuroBoost; Xhale, Inc.; and Skyland Trail. He serves on the board of directors of the American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); GratitudeAmerica, Inc.; NovaDel Pharma, Inc. (2011); and Skyland Trail. He is a stockholder of AbbVie Inc,; Celgene Corporation; CeNeRx BioPharma; PharmaNeuroBoost; Reevax Pharmaceuticals LLC; Seattle Genetics, Inc.; and Xhale, Inc. His other financial income sources or equity of $10,000 or more include American Psychiatric Publishing; BioPharma; CeNeRx NovaDel Pharma, Inc.; Pharmaneuroboost; Revaax Pharmaceuticals LLC; and Xhale, Inc. He holds patents for the following: method and devices for transdermal delivery of lithium (US 6,375,990B1); method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2).

Dr. Caraway has disclosed that he has received research and grant support from Jazz Pharmaceuticals, Inc. and Medtronic, Inc. He is on the speakers bureau of Jazz Pharmaceuticals, Inc. and Medtronic, Inc. He serves as a consultant for Jazz Pharmaceuticals, Inc. and Medtronic, Inc.

Tony Graham, MD (content/peer reviewer) has no disclosures to report.

Robert Kennedy (planning committee) has no disclosures to report.

Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.

Sandra Haas Binford, MAEd (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Unlabeled Use Disclosure

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

CME Outfitters, LLC and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).